McDonald's Stock Drops - Wall Street blames GLP-1 Meds [CBS News]

There's never been a more exciting time to be part of this field. Not only are medications like Semaglutide and Tirzepatide helping our patients achieve meaningful, sustainable weight loss — the impact is big enough that Wall Street analysts are repricing fast food giants because of it.

This week, McDonald's stock dropped after a major financial firm downgraded the company, citing the growing influence of GLP-1 medications. Read that again. The investment thesis for McDonald's now has to account for millions of Americans whose appetite for burgers and fries is pharmacologically quieter.

And it's not just McDonald's. Snack food makers, soda companies, alcohol brands — analysts are modeling demand shifts across the entire "indulgence economy" as these medications spread. When your business depends on people eating and drinking past the point of fullness, a medication that restores normal fullness signals is a genuine threat to the model.

Here's my take, watching from inside a clinic: the food industry spent decades engineering products to override your body's "stop" signals — hyper-palatable, perfectly engineered to make you want one more bite, one more sip. That arms race was never fair. One molecule didn't have a chance against a billion-dollar food science lab.

Until now. GLP-1s are the counter-engineering. And McDonald's stock price dipping is what it looks like when the fight finally got fair.

Your biology was never the problem. Now there's proof on the stock ticker.

-Daryl

Book a FREE consult now <- Click There!

www.pnwmedicalgroup.com

Puyallup: 253-340-2270

Federal Way: 253-363-8877